Coordination gap
The answer is roughly known; the field just hasn't synchronized practice.
Resolves via: Guideline update + dissemination
If rhythm success can replace the stroke-risk score, many ablation patients could stop lifelong anticoagulation and its bleeding risk. If the score still rules, stopping could expose some of them to preventable strokes.
Active since Aug 2025
The debate
6 clinicians quoted on the record
Two 2025 randomized trials found strokes were rare a year after successful ablation, and continued anticoagulation mainly added bleeding, so lifelong therapy in low-to-intermediate-risk patients does more harm than good.
“I think when you look at the totality of the evidence, there are some patients who can stop oral anticoagulation after successful ablation.”
How this gets settled
Who could settle it
Who could fund or run it
Sources & verification
“This means that we should not predict stroke risk from a CHA2DS2VASc score. And it calls into serious question the expert opinion recommendation to continue lifelong anticoagulation after AF ablation.”
+ 3 more on this side
AF often comes back silently after ablation, and these trials enrolled patients with very few events, so the stroke-risk score is still the safer guide until outcomes are proven in broader groups.
“I certainly wouldn’t use these data to justify discontinuing anticoagulants at large, particularly among patients who have a high burden of cardiovascular disease and elevated stroke risk.”
Where the experts land
5–1 on record
Stop in selected patients · 5
Follow the stroke score · 1
“I think when you look at the totality of the evidence, there are some patients who can stop oral anticoagulation after successful ablation.”
Who we found publicly on the record — a snapshot, not a poll of the field. Larger dots are deciders; dashed dots are scan-reported, not yet verified.
Where the field stands
Common ground
In carefully chosen, lower-risk patients who stay arrhythmia-free a year after ablation, strokes are rare and blood thinners cause real bleeding.
The crux
Should rhythm success after ablation override the stroke-risk score when deciding whether to keep a patient on lifelong blood thinners?
Still unknown
Trials in higher-risk patients with structured rhythm monitoring and long follow-up would settle whether stopping is safe beyond the lowest-risk group.
Where do you land?
No votes yet — the measured split appears at 10.
Where the evidence stands
Guidelines still say continue OAC after ablation based on stroke-risk score, not rhythm. ALONE-AF (JAMA 2025) found stopping OAC reduced a composite of stroke/SE/major bleeding, driven by less bleeding. OCEAN (NEJM 2025) found rivaroxaban 15 mg no better than aspirin for stroke/SE/MRI infarcts, with more bleeding, in a very-low-event population and was stopped for futility. Experts warn results do not apply to higher-risk or recurrent-AF patients.
What's settled
4What's still open
4Know an expert who could settle this? Suggest one →
Institutions that could fund, run, or adopt
+ 20 more, each dated and verification-tagged